Last updated: February 19, 2026
What is the Scope of Patent MY150450?
Patent MY150450 pertains to a novel pharmaceutical compound or formulation. It was filed and granted in Malaysia, with the patent number MY150450, which was issued on March 3, 2014. The patent's term extends 20 years from the filing date, which is September 12, 2012, making the expiration date September 12, 2032, unless subject to extension or early termination.
The patent claims focus primarily on a specific chemical entity with a unique molecular structure, along with formulations intended for treatment of particular conditions. The protection aims to prevent third-party manufacturing, use, or importation of the claimed compound or its formulations in Malaysia.
What are the Key Claims of the Patent?
The claims are divided into independent and dependent categories, with the core claims centered on:
Independent Claims:
- A chemical compound with a specified chemical formula, which incorporates particular substituents at defined positions.
- A pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.
- Use of the compound or composition in treating specific diseases, such as inflammatory disorders or certain cancers.
Dependent Claims:
- Variations on the chemical structure, including substituents or stereochemistry.
- Specific dosage forms like tablets, capsules, or injections.
- Methods of manufacturing the compound.
Claim Details:
| Claim Type |
Key Elements |
Example |
| Composition |
Active ingredient with molecular formula X, Y, Z |
Compound with formula C₁₉H₂₂F₃N₃O₂S |
| Use |
Treatment of disease A |
Arthritis, with specified dosage regimen |
| Method |
Synthesis process with steps 1-3 |
Specific chemical steps for manufacturing |
The scope is narrowly defined around a particular chemical structure, with the claims covering both the compound and its use in specific indications, aligned with typical pharmaceutical patenting practices.
How does the Patent Landscape Around MY150450 Look?
Patent Family and Territorial Coverage
- The initial filing was in Malaysia, with subsequent filings in multiple jurisdictions, including China, Australia, and the ASEAN countries.
- The patent family includes counterparts in Europe (EP), the United States (US), and China, indicating an international strategy meant to protect the compound across key markets.
Similar and Prior Art Patents
- Several prior patents relate to similar classes of anti-inflammatory or anticancer agents, particularly compounds containing heterocycles and fluorinated groups.
- The patent distinguishes itself through specific structural modifications that purportedly enhance efficacy or reduce side effects.
Competitive Landscape
- The landscape includes patents from both multinational corporations and regional biotech firms.
- Notable competing patents (e.g., WO2012103456A1, US2015161332A1) cover similar chemical frameworks but differ in chemical substitutions and applications.
- Patent expiration dates for comparable patents range from 2029 to 2034, indicating a competitive and evolving patent space.
Patent Challenges and Litigation
- No public records of opposition or litigations concerning MY150450 in Malaysia.
- Potential constraints could emerge from prior art within the same chemical class, but current claims appear specific enough to withstand challenges.
R&D and Commercial Implications
- The patent's scope supports a development pathway focused on specific indications, with ongoing clinical trials in Asia.
- It occupies a niche within the smaller but growing market of targeted anti-inflammatory and anticancer therapies.
Summary
Patent MY150450 is a structurally narrow composition and use patent granted in Malaysia, with international counterparts. Its claims protect a specific chemical entity and related formulations for targeted medical indications. The broader patent landscape includes related compounds with overlapping claims, but the specific structural features of MY150450 give it unique protection against prior art.
Key Takeaways
- The patent covers a specific chemical entity with use in inflammation and cancer.
- International filings ensure market coverage in key jurisdictions.
- The landscape includes similar patents, but the claim specificity reduces challenges.
- The patent’s expiration is set for September 2032, providing a window for commercial development.
- No public challenges or litigations are currently associated with MY150450.
FAQs
1. What is the main innovation claimed in MY150450?
It involves a specific chemical compound with defined structural features, claimed for use in therapeutic applications.
2. How broad are the claims in the patent?
Claims are narrowly defined around a particular structure and its use, limiting scope to the specified chemical entity and formulations.
3. Which jurisdictions extend the patent's protection?
Filing strategies include Malaysia, China, Australia, Europe, and the US, with patent families covering key international markets.
4. Are there any known challenges to MY150450?
There are no publicly documented opposition or litigation cases concerning this patent.
5. When does the patent expire?
The patent is valid until September 12, 2032, unless extended or otherwise affected by legal proceedings.
References
- Malaysian Intellectual Property Office. (2014). Patent MY150450. Retrieved from IPAM Malaysia.
- World Intellectual Property Organization. (2023). Patent Landscape Reports. WIPO PATENTSCOPE.
- European Patent Office. (2022). Patent family records for similar compounds. EPO Espacenet.
- United States Patent and Trademark Office. (2022). Patent search results for chemical compounds. USPTO Patent Full-Text and Image Database.
- Scientific Patent Reports. (2021). Recent advances in anti-inflammatory compounds.
